  | 
							
								
								
	
	
		  | 
		
			 
			 
		 | 
	 
	 |  
	 |  
	
		
		
		
			
			
				| Tamoxifen Citrate  |  
				
				
				
				
				
				  |  
				| Tamoxifen Citrate  |  
				
				
				
				
				
				
				  |  
				Tamoxifen Citrate 
  Synonyms: kessar  noltam  tamofen 
  CAS: 54965-24-1 
  EINECS: 259-415-2 
  Assay: 99%-101%. USP31
  Packing: 1Kg/foil bag.
  Delivery: Courier.
  MF: C32H37NO8 
  MW: 563.64
  Character: White crystalline powder. MP 140-144¡ÆC.
  Usage: For the treatment of advanced, recurrent breast cancer and ovarian cancer and other illnesses. Used as an antineoplastic raw materials.
  Biological Activity: Estrogen receptor antagonist/partial agonist. Selective and potent inhibitor of mammalian sterol isomerase. Neuroprotective in female rats in vivo . Also high affinity agonist at the membrane estrogen receptor GPR30.
   
  |  
				
				
				
				
				
				
				
				  |  
				Tamoxifen Citrate 
  Synonyms: kessar  noltam  tamofen 
  CAS: 54965-24-1 
  EINECS: 259-415-2 
  Assay: 99%-101%. USP31
  Packing: 1Kg/foil bag.
  Delivery: Courier.
  MF: C32H37NO8 
  MW: 563.64
  Character: White crystalline powder. MP 140-144¡ÆC.
  Usage: For the treatment of advanced, recurrent breast cancer and ovarian cancer and other illnesses. Used as an antineoplastic raw materials.
  Biological Activity: Estrogen receptor antagonist/partial agonist. Selective and potent inhibitor of mammalian sterol isomerase. Neuroprotective in female rats in vivo . Also high affinity agonist at the membrane estrogen receptor GPR30.
   
  |  
				
				
				
					
						
							| Industrial field | 
							pharmaceutical | 
						 
					 | 
				 
				
			 
			
		 | 
		
		
		
			
				
				
				  |  
				
					| 
						
							
					 | 
				 
				 |  
				
				
				
					| 
						
					 | 
				 
				
					
						
							  |  
							
								
									
									
									
										| There are no existing companies to distribute selected chemical product |  
									
									 
									
								 | 
							 
							  |  
						 	
					 | 
				 
			 
			
			
		 | 
	 
 
									
								 |